Cadrenal Therapeutics Announces Formation of Scientific Advisory Board
Cadrenal Therapeutics Announces Formation of Scientific Advisory Board PONTE VEDRA, Florida – August 18, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the formation of its Scientific Advisory Board (SAB) in support of the development of its Phase-3 ready tecarfarin […]
American Heart Association Scientific Sessions | November 5-7, 2022
Cadrenal to attend the American Heart Association (AHA) Scientific Sessions on November 5-7, 2022 in Chicago, Illinois. Conference Link: https://professional.heart.org/es/meetings/scientific-sessions
American Society of Nephrology: Kidney Week 2022 | November 3-6, 2022
Cadrenal to attend ASN Kidney Week 2022 on November 3-6, 2022 in Orlando, Florida. Conference Link: https://www.asn-online.org/education/kidneyweek/
BioFlorida Annual Conference | November 2-4, 2022
Cadrenal to attend the BioFlorida Annual Conference on November 2-4, 2022 in Miami, Florida. Conference Link: https://www.bioflorida.com/events/EventDetails.aspx?id=1633993&group=
BIO International Convention | June 13-16, 2022
Cadrenal to attend the BIO International Convention on June 13-16, 2022 in San Diego, California. Conference Link: https://www.bio.org/events/bio-international-convention
Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer
Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer PONTE VEDRA, Florida – July 25, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Douglas W. Losordo, MD, FACC, FAHA as Chief Medical Officer. Quang […]
Cadrenal Therapeutics Announces Confidential Submission of Draft Registration Statement Related to Proposed Public Offering
Cadrenal Therapeutics Announces Confidential Submission of Draft Registration Statement Related to Proposed Public Offering PONTE VEDRA, Florida – July 15, 2022 – Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, announced today that it has confidentially submitted a draft registration statement on […]
Cadrenal Therapeutics Appoints Matthew K. Szot as Chief Financial Officer
Cadrenal Therapeutics Appoints Matthew K. Szot as Chief Financial Officer PONTE VEDRA, Florida – May 17, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Matthew K. Szot as the Company’s Chief Financial Officer (“CFO”). Szot brings more […]
Cadrenal Therapeutics Acquires Tecarfarin from Horizon
Cadrenal Therapeutics Acquires Tecarfarin from Horizon PONTE VEDRA, Florida – April 1, 2022 – Cadrenal Therapeutics, Inc. (“Cadrenal”) has acquired the rights to tecarfarin from Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, […]
Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
The aim of this narrative review is to examine and discuss current evidence on AF, stroke occurrence, and prevention in patients with ESRD on HD as well as the opportunities of DOAC use in this clinically challenging setting. Authors: Oliver Königsbrügge, MD, PhD and Cihan Ay, MD Abstract: Atrial fibrillation (AF) is a frequent comorbid condition in […]
